---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pharmacokinetics"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Pharmacokinetics. Topics: Plasma pharmacokinetic parameters after intrathecal administration; Absorption, distribution, and elimination; Cerebrospinal fluid and plasma pharmacokinetics after intracerebroventricular dosing in the NIH phase 1 trial; Central nervous system distribution after a single intrathecal dose in cats; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Plasma pharmacokinetic parameters after intrathecal administration

> “The pharmacokinetic parameters of adrabetadex in the plasma following intrathecal administration of LEMBAZ in patients with NPC are summarized in Table 7.”
> “Plasma AUC0-last increased in an approximately dose proportional manner and plasma Cmax increased less than dose proportionally at a dose that ranged from 200 to 900 mg.”
> “No adrabetadex accumulation in plasma or CSF was observed after repeated LEMBAZ administration.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

| Parameter, mean (CV%) | 200 mg | 300 mg | 600 mg | 900 mg |
| --- | --- | --- | --- | --- |
| AUC0-last (hr·mcg/mL) | “39 (19%)” | “51 (14%)” | “101 (34%)” | “167 (40%)” |
| Cmax (mcg/mL) | “2.4 (33.7%)” | “4.5 (77.3%)” | “6.3 (37%)” | “8.4 (84.3%)” |

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.3-2"></a>

### Absorption, distribution, and elimination

> “Following intrathecal injection of LEMBAZ, the median time to peak plasma concentration (Tmax) of adrabetadex ranged from 4 to 8 hours.”
> “The absolute bioavailability of adrabetadex following intrathecal administration of LEMBAZ has not been determined.”
> “Following intrathecal administration of LEMBAZ, the mean apparent volume of distribution of adrabetadex at steady state was 61.8 L in patients with NPC.”
> “Plasma protein binding of adrabetadex is less than 10% over the concentration range from 1 to 10 micromole.”
> “The mean plasma half-life of adrabetadex was 14.7 hours, following intrathecal LEMBAZ administration.”
> “Metabolism: The metabolism of adrabetadex has not been characterized.”
> “Excretion: Adrabetadex is expected to be predominantly cleared by urinary excretion.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-2.1.2.6.3-3"></a>

### Cerebrospinal fluid and plasma pharmacokinetics after intracerebroventricular dosing in the NIH phase 1 trial

> “Three NPC1 subjects were admitted to the NIH Clinical Center Intensive Care Unit and an Ommaya reservoir was surgically placed on the nondominant side.”
> “Following the ICV injection of 50 mg HP-β-CD, high CSF concentrations of HP-β-CD were observed with the Cmax ranging from approximately 520 to 1,500 μg/ml in three patients (Table 4).”
> “The mean Vdss of ∼130 ml was approximately to the reported CSF volume in humans.”
> “The estimated mean t1/2 for HP-β-CD in CSF was 6.58 h based on the RP-UPLC-MS/MS method and 10.1 h based on the 2D-LC-IF-MS/MS method.”
> “The mean Cmax and AUC of HP-β-CD in plasma were less than 0.3% of the corresponding CSF PK parameters.”
> “The estimated mean t1/2 values for HP-β-CD in plasma were 12.4 h based on the RP-UPLC-MS/MS method and 15.1 h based on the 2D-LC-IF-MS/MS method.”

Source: [Jiang et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4076072/)

<a id="topic-2.1.2.6.3-4"></a>

### Central nervous system distribution after a single intrathecal dose in cats

> “In this study, tissue distribution was investigated in normal cats that received a single 120‐mg dose of [14C]‐HP‐β‐CD (approximately 200 μCi/cat) via the cerebellomedullary cistern (CBMC) and lumbar cistern.”
> “HP‐β‐CD‐derived radioactivity penetrated into the deeper parts of the central nervous system with the highest concentration at 4 hours (403 μg Eq/g or 0.28 mM) and remained high (49.7 μg Eq/g or 0.03 mM) at 24 hours.”
> “The relatively long half‐life (11‐30 hours) in cerebral ventricles and the subarachnoid space surrounding the brain and spinal cord might contribute to the efficacy of HP‐β‐CD in NPC1 cats.”

Source: [Kao et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7317750/)

<a id="topic-2.1.2.6.3-5"></a>

### Brain distribution and duration of exposure in mice and cats: company nonclinical studies

> “Central administration distributes adrabetadex broadly throughout the CNS, reaching deep and superficial brain regions at human-equivalent doses.”
> “Sustained CNS concentrations support once-every-2 weeks dosing to counter ongoing cholesterol accumulation.”
> “Superficial, cortical regions show 2.3x higher levels of adrabetadex two weeks post-dose than deep grey matter and white matter”

Source: [Burchard et al. (2026a)](https://medical.berentx.com/wp-content/uploads/2026/05/APMRF2026-P18.1-MOA.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
